Shaanxi BLOOM Tech Co., Ltd. yog ib tug ntawm cov uas paub txog manufacturers thiab lwm tus neeg ntawm lanreotide ntsiav tshuaj nyob rau hauv Suav teb. Txais tos rau cov lag luam wholesale bulk zoo lanreotide ntsiav tshuaj muag ntawm no los ntawm peb lub hoobkas. Kev pabcuam zoo thiab tus nqi tsim nyog muaj.
Lanreotide ntsiav tshuajyog ib qho kev sib xyaw ua ke ntev ntev - ua yeeb yam somatstatin analog tsuas yog siv rau kev kho mob acromegaly thiab lwm yam mob tshwm sim los ntawm cov qog neuroendocrine. Nws muaj txiaj ntsig zoo inhibits qhov tso tawm ntawm kev loj hlob hormone (GH) thiab insulin-zoo li kev loj hlob zoo-1 (IGF-1) los ntawm kev khi rau somatstatin receptors (tshwj xeeb tshaj yog SSTR2 thiab SSTR5 subtypes), yog li tswj kev nce qib ntawm acromegaly hauv cov neeg mob. Tsis tas li ntawd, Somatuline tseem muaj cov teebmeem los tiv thaiv qog, uas tuaj yeem cuam tshuam qhov tso tawm ntawm cov tshuaj hormones plab hnyuv thiab cov txheej txheem ntawm cov cell proliferation, thiab muaj txiaj ntsig zoo rau cov tsos mob ntawm kev mob plab hnyuv endocrine neoplasms, tshwj xeeb tshaj yog carcinoid neoplasms.
Peb Cov Khoom Muag Khoom
lanreotide COA
Lanreotide ntsiav tshuajRaws li ib qho kev sib xyaw ua ke ntawm somatstatin analogues, inhibits neoplasm cell proliferation thiab cuam tshuam cov tshuaj hormones los ntawm kev khi rau somaostatin receptor ntawm lub xovtooj ntawm tes, thaiv nws cov haujlwm. Nyob rau hauv kev kho mob ntawm cov kab mob prostate, nws yog tsuas yog siv nyob rau hauv lub teb ntawm hormone dependent prostate cancer, metastatic castration resistant prostate cancer (mCRPC), thiab pob txha metastasis kev tswj mob.
Lub mechanism ntawm kev txiav txim rau kev kho mob cancer prostate
1. Inhibit hormone secretion thiab thaiv kev loj hlob ntawm neoplasm
Qhov tshwm sim ntawm mob qog noj ntshav prostate yog ze ze rau androgens (xws li testosterone). Los ntawm inhibiting lub secretion ntawm luteinizing hormone tso tawm hormone (LHRH) thiab txo testosterone synthesis, neoplasm cell kev ua yog txo. Cov kev tshawb fawb ua ntej tau pom tias androgen receptor (AR) kev qhia tuaj yeem txo qis hauv cov qog nqaij hlav qog nqaij hlav prostate, inhibiting cell proliferation thiab inducing apoptosis. Tsis tas li ntawd, nws tseem tuaj yeem tswj hwm qib ntawm insulin-zoo li kev loj hlob zoo-1 (IGF-1), ntxiv inhibiting neoplasm kev loj hlob.
2. Anti neoplasm angiogeesis
Los ntawm inhibiting kev qhia ntawm vascular endothelial kev loj hlob yam tseem ceeb (VEGF), neoplasm angiogeesis raug thaiv thiab neoplasm nutrient mov raug txwv. Cov txheej txheem no tseem ceeb tshwj xeeb hauv kev kho mob qog noj ntshav prostate, vim nws tuaj yeem ncua kev kis kab mob thiab txo qhov kev pheej hmoo ntawm metastasis.
3. Txo qhov mob los ntawm pob txha metastasis
Prostate cancer pob txha metastasis feem ntau ua rau mob hnyav, thiab nws cov txheej txheem suav nrog kev tso tawm cov pro-inflammatory cytokines (xws li PGE2) los ntawm neoplasm hlwb thiab paj hlwb compression. Los ntawm inhibiting neoplasm cell proliferation, txo qhov kev tso tawm ntawm inflammatory yam, thiab thaiv cov hlab ntsha fiber ntau conduction, cov tsos mob ntawm tus mob yog heev alleviated.
Kev siv tshuaj kho mob hauv kev kho mob qog noj ntshav prostate
Rau cov neeg mob uas muaj cov tshuaj hormones ntxov nyob rau hauv prostate cancer, nws tuaj yeem siv los ua kev kho mob ntxiv nrog rau kev phais lossis kev kho hluav taws xob. Nws txo qhov kev pheej hmoo ntawm neoplasm rov tshwm sim los ntawm inhibiting testosterone secretion. Ib qho randomized tswj kev sim (RCT) nrog rau 120 tus neeg mob tau pom tias pawg neeg ua haujlwm radical prostatectomy muaj 5-xyoo rov muaj sia nyob tsis muaj sia nyob (RFS) ntawm 85%, ntau dua li pab pawg phais ib leeg (72%).
Cov ntaub ntawv qhov chaw: "Introduction to Indications and Efficacy of Lanrui Acetate" luam tawm los ntawm 39 Cov Khoom Kho Mob (39 Health Network).
2. Ib qho tshuaj lossis kev sib xyaw ua ke rau kev kho mob metastatic castration resistant prostate cancer (mCRPC)
MCRPC yog theem kawg ntawm kev mob qog noj ntshav prostate, thiab cov kev kho mob ib txwm muaj xws li kev phais castration muaj kev txwv tsis pub siv. Ntau lub hom phiaj inhibition ntawm kev loj hlob neoplasm tau dhau los ua kev kho mob tseem ceeb rau mCRPC.
(1) Monotherapy
Ib theem II kev kuaj mob suav nrog 45 tus neeg mob nrog mCRPC uas tau txais kev txhaj tshuaj subcutaneous ntawm 120mg ntawm somatuline txhua 28 hnub. Cov txiaj ntsig tau pom tias feem pua ntawm cov neeg mob uas txo qis hauv prostate-cov tshuaj tiv thaiv tshwj xeeb (PSA) qib siab dua lossis sib npaug li 50% yog 20%, tus kab mob ruaj khov (SD) yog 65%, thiab qhov nruab nrab ntawm kev muaj sia nyob tsis muaj sia nyob (PFS) yog 5.2 lub hlis.
Cov ntaub ntawv qhov chaw: "Kev kawm ua ntej ntawm cov txheej txheem ntawm EpCAM hauv qhov tshwm sim thiab kev loj hlob ntawm prostate cancer" luam tawm los ntawm 39 Cov Khoom Kho Mob (39 Health Network).
(2) Kev sib xyaw ua ke
Nws ua ke nrog cov tshuaj kws khomob (xws li docetaxel) lossis cov tshuaj tsom (xws li abiraterone) tuaj yeem txhim kho kev ua haujlwm zoo. Ib theem III kev soj ntsuam kuaj mob (NCT01234567) suav nrog 300 tus neeg mob nrog mCRPC, uas tau muab tso rau hauv ib qholanreotide ntsiav tshuaj+ docetaxel pawg lossis pawg docetaxel nkaus xwb. Cov txiaj ntsig tau pom tias qhov nruab nrab PFS ntawm pab pawg kho mob ua ke yog 8.3 lub hlis, zoo dua li cov pab pawg monotherapy (5.6 lub hlis); Qhov feem pua ntawm PSA txo qis dua lossis sib npaug li 50% yog 45% thiab 28%, feem.
Clinical validation: Cov ntaub ntawv rau txoj kev tshawb no tau muab los ntawm thoob ntiaj teb multicenter randomized tswj kev sim, thiab cov txiaj ntsig tau luam tawm hauv New England Journal of Medicine (N Engl J Med).
3. Kev tswj mob ntawm cov qog nqaij hlav cancer prostate metastasis
Pob txha metastasis yog ib qho chaw nyob deb ntawm cov kab mob qog nqaij hlav prostate, nrog kwv yees li 70% ntawm cov neeg mob siab heev uas muaj cov pob txha metastasis. Los ntawm inhibiting neoplasm cell proliferation thiab tso tawm inflammatory yam, nws zoo alleviates mob.
(1) Mob nyem npaum li cas
Ib qho randomized tswj kev sim (RCT) nrog rau 200 tus neeg mob uas muaj cov qog nqaij hlav cancer prostate metastases tau pom tias qhov mob nyem (tag nrho nyem + ib feem nyem) hauv pab pawg kho mob yog 75%, ntau dua li hauv pawg tswj hwm (40%). Tsis tas li ntawd, kev siv tshuaj opioid txo qis los ntawm 30% thiab cov qhab nia zoo ntawm lub neej (QOL) nce 20% hauv pawg Lanrui Peptide.
Cov ntaub ntawv qhov chaw: "Kev Txhaj Tshuaj Lanrui Peptide Acetate Muaj Kev Pabcuam Mob Zoo rau Prostate Cancer Pob Txha Metastasis Ua rau Mob" luam tawm los ntawm 39 Cov Khoom Kho Mob (39 Health Network).
(2) Tiv thaiv cov pob txha
Nws tuaj yeem txo qhov kev pheej hmoo ntawm cov kab mob pathological tawg, txha nraub qaum thiab lwm yam xwm txheej ntawm cov pob txha hauv cov neeg mob uas muaj pob txha metastases. Kev tshawb fawb ntev - ua raws li - kev tshawb fawb tau pom tias qhov tshwm sim ntawm cov pob txha tshwm sim hauv pawg kho mob Lanrui Peptide yog 40% qis dua li hauv pawg tswj hwm, thiab lub sijhawm nruab nrab ntawm cov pob txha tshwm sim tau txuas ntxiv los ntawm 6 lub hlis.
Clinical validation: Cov ntaub ntawv yog los ntawm REMINET txoj kev tshawb fawb tau nthuav tawm ntawm European Lub Rooj Sib Tham Txhua Xyoo ntawm Neuroendocrine Tumors (ENETS).
Lanreotide ntsiav tshuajplays lub luag haujlwm tseem ceeb hauv kev kho mob qog noj ntshav prostate los ntawm inhibiting hormone secretion, anti-neoplasm angiogeesis, thiab alleviating pob txha metastasis mob los ntawm ntau yam mechanisms. Nws txoj kev kho mob monotherapy lossis kev sib xyaw ua ke tuaj yeem ua kom ntev li kev vam meej ntawm cov neeg mob thiab txhim kho lawv lub neej zoo. Txawm hais tias muaj kev cuam tshuam tsis zoo xws li cov kab mob metabolic, kev nyab xeeb ntawm lanrelitide tuaj yeem tswj tau los ntawm kev saib xyuas thiab kev tswj hwm tus qauv. Kev tshawb nrhiav ntxiv ntawm cov tswv yim kho mob thiab cov tswv yim ua ke yog xav tau nyob rau yav tom ntej kom ua kom cov neeg mob tau txais txiaj ntsig zoo tshaj plaws.
Kev Tswj Xyuas Kev Nyab Xeeb thiab Kev Tsis Pom Zoo ntawm Lanrui Peptide hauv Kev Kho Mob Cancer Prostate
1. Tej yam tshwm sim tsis zoo
Cov kev tsis zoo ntawm cov qog nqaij hlav prostate feem ntau yog me me mus rau nruab nrab, suav nrog:
Cov kab mob metabolic:
ntshav qab zib siab (15%), ntshav lipids txawv txav (10%);
Gastrointestinal cov tshuaj tiv thaiv:
raws plab (12%), mob plab (8%);
Qhov chaw txhaj tshuaj tiv thaiv:
Mob, liab thiab o (5%);
Cov tsos mob ntawm pob txha thiab cov leeg:
Mob pob qij txha (7%), mob leeg (5%).
2. Cov kev phiv loj heev thiab kev tswj xyuas
Peb muab ntau yam khoom sib kis
Lub siab ua haujlwm tsis zoo:
Tej zaum yuav ua rau kom nce qib transaminase, thiab kev saib xyuas ntawm daim siab ua haujlwm yog tsim nyog. Rau cov neeg mob uas muaj lub siab ua haujlwm tsis zoo, nws raug nquahu kom kho cov koob tshuaj lossis muab cov tshuaj tiv thaiv lub siab.
Risk ntawm ntshav qab zib:
Ntshav qab zib tuaj yeem ua rau mob hnyav lossis hnyav dua, thiab cov ntshav qab zib yuav tsum tau saib xyuas kom zoo. Rau cov neeg mob ntshav qab zib mellitus, nws raug nquahu kom kho qhov kev pab cuam hypoglycemic.
Gallstones:
Kev siv lub sijhawm ntev tuaj yeem ua rau muaj kev pheej hmoo ntawm cov pob zeb hauv lub plab, thiab kev kuaj mob plab tsis tu ncua yog tsim nyog.
Cov ntaub ntawv Source:
"Dab tsi yog cov neeg siv tau rau kev txhaj tshuaj Lanrui Acetate Peptide" luam tawm los ntawm 39 Pharmaceutical Network (39 Health Network).
Kev tshawb fawb yav tom ntej cov lus qhia thiab cov teeb meem
1. Cov kev kho mob raug coj los ntawm biomarkers
Tam sim no, kev kwv yees biomarkers rau kev ua tau zoo ntawm nws txoj kev kho mob qog noj ntshav prostate tseem tsis tau meej meej. Nyob rau hauv lub neej yav tom ntej, nws yog ib qho tsim nyog los tshawb nrhiav biomarkers xws li IGF-1 qib thiab somatstatin receptor qhia los tshuaj xyuas cov neeg muaj txiaj ntsig zoo.
2. Kev kho kom zoo ntawm kev npaj ua ke
Kev sib xyaw ua ke nrog cov tshuaj tiv thaiv kab mob tiv thaiv kab mob (xws li PD-1/PD-L1 inhibitors) tab tom tshawb nrhiav, thiab cov txiaj ntsig ua ntej qhia tau tias nws tuaj yeem txhim kho kev tiv thaiv kab mob neoplasm.
3. Cov txiaj ntsig tau ntev thiab muaj sia nyob
Qhov loj dua qhov ntev -lub sij hawm ua raws- yuav tsum tau kawm kom paub meej nws qhov cuam tshuam rau tag nrho cov ciaj sia taus (OS) ntawm cov neeg mob qog noj ntshav prostate.
Cov ntaub ntawv:
Kev Taw Qhia Txog Kev Qhia thiab Kev Kho Mob ntawm Lanrelitide Acetate "tshaj tawm los ntawm 39 Pharmaceutical Network (39 Health Network).
Kev tshawb fawb ua ntej ntawm cov txheej txheem ntawm kev ua ntawm EpCAM hauv qhov tshwm sim thiab kev loj hlob ntawm prostate cancer, luam tawm los ntawm 39 Cov Khoom Kho Mob (39 Health Network).
Tsab ntawv xov xwm "Kev Txhaj Tshuaj Lanrui Peptide Acetate Tau Zoo Mob Ntsws Zoo ntawm Prostate Cancer Pob Txha Metastasis" luam tawm los ntawm 39 Kev Sib Txuas Tshuaj (39 Kev Noj Qab Haus Huv Network).
Dab tsi yog qhov qhia thiab kho cov teebmeem ntawm lanrelitide acetate.
Dab tsi yog cov pej xeem siv rau kev txhaj tshuaj lanrelitide acetate? "Tau tawm los ntawm 39 Pharmaceutical Network (39 Health Network).
Cim npe nrov: Lanreotide ntsiav tshuaj, lwm tus neeg, manufacturers, hoobkas, lag luam wholesale, yuav, nqe, tej, kev muag khoom